Stocklytics Platform
Asset logo for symbol PEPG
Asset logo for symbol PEPG



AI Deep-Learning Forecast (PEPG)

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

PepGen (PEPG) Stocklytics Forecast

PepGen Inc. (PEPG) is a biotechnology company focused on developing transformative therapies for patients with neuromuscular diseases. The company's innovative approach combines advanced genetic techniques with state-of-the-art delivery systems, allowing for targeted treatment of specific disease-causing mutations. With a strong pipeline of potential therapeutics, PepGen is well-positioned to address the significant unmet need in this space.

Looking ahead, there is considerable optimism surrounding the future of PepGen and its stock price. Industry analysts and experts have provided positive forecasts and price targets for the company, suggesting a potential for significant growth. While it's important to note that these predictions are not guarantees of future performance, they do highlight the confidence in PepGen's potential.

add PepGen to watchlist

Keep an eye on PepGen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

What is the analyst price prediction for PepGen (PEPG) stock?

Analysts have set a target price of $24.73 for PepGen (PEPG), based on forecasts from 15 analysts. The predicted price range extends from a high of $40 to a low of $16. This represents a potential increase of up to 137.53% and a decrease of -4.99% from the current price of $16.84. These forecasts are as of 2019 Aug 06.

What are the analyst ratings for PepGen (PEPG) stock?

Currently, there are no analyst ratings available for PepGen (PEPG), possibly due to insufficient coverage or recent updates.

What is the AI price prediction for PepGen (PEPG) stock?

At present, there is no AI or machine-learning-based price prediction available for PepGen (PEPG) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.


Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level